Invasive procedures in the outpatient setting: Managing the short-acting acenocoumarol and the long-acting phenprocoumon

Summary

Treatment with vitamin K antagonists (VKAs) has to be interrupted when invasive procedures are planned. We compared various methods of interruption in patients on acenocoumarol or phenprocoumon in a prospective study. In patients on acenocoumarol (n=141), 99 stopped three days before the intervention and 42 stopped two days before. All patients on phenprocoumon (n=111) received vitamin K two days before the intervention, and 55 of these patients discontinued phenprocoumon, whereas 56 did not stop. In a subset of 30 patients we determined International Normalized Ratios (INRs) and coagulation factors II,VII, X and protein C. The mean INR after stopping acenocoumarol for three days was significantly lower than after two days (1.1 vs. 1.3, p=<0.0001), but its clinical relevance may be trivial. In patients using phenprocoumon, the mean INR on the day of the intervention was only slightly lower after stopping the VKAs (1.5 vs. 1.6, p=0.0407), but a similar proportion of patients had an INR ≤1.4. On the day of the intervention, in the acenocoumarol group mean plasma levels of all coagulation factors were higher than 50% and in the phenprocoumon group higher than 25%. We conclude that acenocoumarol can be stopped two days before an invasive procedure that is associated with a low or moderate bleeding risk and three days before an intervention with a higher bleeding risk. For phenprocoumon, administration of vitamin K two days before an intervention results in an acceptable INR during the intervention, regardless whether phenprocoumon is interrupted or not.

Keywords

Acenocoumarol - phenprocoumon - invasive procedures - coagulation factors

• References

• 1 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists.. Chest 2004; 204S-233.
• 2 Haustein KO. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.. Sem Thromb Hemost 1999; 25: 5-11.
• 3 Dunn A, Turpie AGG. Perioperative management of patients receiving oral anticoagulants.. Arch Int Med 2003; 163: 901-908.
• 4 Kearon C. Management of anticoagulation in patients who require invasive procedures.. Semin Vasc Med 2003; 3: 285-297.
• 5 Douketis J. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.. Thromb Res 2003; 108: 3-13.
• 6 Thorn M, Rosendaal FR. Oral anticoagulants in surgical procedures: risks and recommendations.. Br J Haematol 2003; 123: 676-682.
• 7 White RH, McKittrick T, Hutchinson R. et al. Temporary discontinuation of warfarin therapy: changes in the International Normalized Ratio.. Ann Intern Med 1995; 122: 40-42.
• 8 Wentzien TH, O’Reilly RA, Kearns PJ. Prospective evaluation of anticoagulant reversal with oral vitamin K₁ while continuing warfarin therapy unchanged.. Chest 1998; 114: 1546-1550.
• 9 White RH, Minton SM, Andya MD. et al. Temporary reversal of anticoagulation using oral vitamin K.. J Thromb Thrombolysis 2000; 10: 149-153.
• 10 Crowther MA, Ageno W, Schnurr T. et al. Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin.. Haematologica 2005; 90: 137-139.
• 11 Larson BJG, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.. Chest 2005; 127: 922-927.
• 12 Ulrich S, Debrunner J, Stoll S. et al. A single dose of oral vitamin K effectively reverses oral anticoagulation with phenprocoumon during heart catheterisation.. Swiss Med Wkly 2006; 136: 691-695.